FdaApplication
BLA 125377
Identifiers
- fda_app_no: BLA125377
Properties
| Property | Value |
|---|---|
| applicant_name | Bristol-Myers Squibb Company |
| application_type | BLA |
| approval_date | 2011-03-25 |
Revenue by product
YERVOY
| Period | Revenue |
|---|---|
| Q2 2026 | $769.0M |
| Q1 2026 | $651.0M |
| Q4 2025 | $810.0M |
| Q3 2025 | $739.0M |
| Q2 2025 | $728.0M |
| Q1 2025 | $624.0M |
| Q4 2024 | $675.0M |
| Q3 2024 | $642.0M |
| Q2 2024 | $630.0M |
| Q1 2024 | $583.0M |
| Q4 2023 | $566.0M |
| Q3 2023 | $579.0M |
| Q2 2023 | $585.0M |
| Q1 2023 | $508.0M |
| Q4 2022 | $568.0M |
| Q3 2022 | $523.0M |
| Q2 2022 | $525.0M |
| Q1 2022 | $515.0M |
| Q4 2021 | $545.0M |
| Q3 2021 | $515.0M |
| Q2 2021 | $510.0M |
| Q1 2021 | $456.0M |
| Q4 2020 | $471.0M |
| Q3 2020 | $446.0M |
| Q2 2020 | $369.0M |
| Q1 2020 | $396.0M |
| Q4 2019 | $385.0M |
| Q3 2019 | $353.0M |
| Q2 2019 | $367.0M |
| Q1 2019 | $384.0M |
| Q4 2018 | $384.0M |
| Q3 2018 | $382.0M |
| Q2 2018 | $315.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
YERVOY
| Period | Revenue |
|---|---|
| Q2 2026 | $769.0M |
| Q1 2026 | $651.0M |
| Q4 2025 | $810.0M |
| Q3 2025 | $739.0M |
| Q2 2025 | $728.0M |
| Q1 2025 | $624.0M |
| Q4 2024 | $675.0M |
| Q3 2024 | $642.0M |
| Q2 2024 | $630.0M |
| Q1 2024 | $583.0M |
| Q4 2023 | $566.0M |
| Q3 2023 | $579.0M |
| Q2 2023 | $585.0M |
| Q1 2023 | $508.0M |
| Q4 2022 | $568.0M |
| Q3 2022 | $523.0M |
| Q2 2022 | $525.0M |
| Q1 2022 | $515.0M |
| Q4 2021 | $545.0M |
| Q3 2021 | $515.0M |
| Q2 2021 | $510.0M |
| Q1 2021 | $456.0M |
| Q4 2020 | $471.0M |
| Q3 2020 | $446.0M |
| Q2 2020 | $369.0M |
| Q1 2020 | $396.0M |
| Q4 2019 | $385.0M |
| Q3 2019 | $353.0M |
| Q2 2019 | $367.0M |
| Q1 2019 | $384.0M |
| Q4 2018 | $384.0M |
| Q3 2018 | $382.0M |
| Q2 2018 | $315.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| YERVOY | IPILIMUMAB | 50MG/10ML (5MG/ML) | INJECTABLE;INJECTION |
| YERVOY | — | 200MG/40ML (5MG/ML) | Injection |
2 products